• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMerck

The Two Mercks Are Locking Horns in a Naming Trademark Spat

By
Sy Mukherjee
Sy Mukherjee
By
Sy Mukherjee
Sy Mukherjee
April 18, 2016, 5:18 PM ET
RAHWAY, NJ - NOVEMBER 29:  A man walks by a sign at a Merck plant November 29, 2005 in Rahway, New Jersey. U.S. pharmaceutical giant Merck, announced plans to cut some 7,000 jobs, or 11 percent of its global workforce, by the end of 2008. (Photo by Marko Georgiev/Getty Images)
RAHWAY, NJ - NOVEMBER 29: A man walks by a sign at a Merck plant November 29, 2005 in Rahway, New Jersey. U.S. pharmaceutical giant Merck, announced plans to cut some 7,000 jobs, or 11 percent of its global workforce, by the end of 2008. (Photo by Marko Georgiev/Getty Images)Photograph by Marko Georgiev — Getty Images

There are not one but two drug-making firms called “Merck,” and their relationship spans centuries of corporate pharmaceutical history. So perhaps it’s not too surprising that one of the biggest ongoing scuffles between the two companies in recent times centers on their shared name.

America’s Merck & Co. (MRK) is one of the largest pharma companies in the country and the world. But it was originally part of German parent company Merck KGaA, which actually reserves the rights to the “Merck” name in the vast majority of the world (and is, for its part, one of the oldest pharma companies in the world).

The U.S. Merck is branded Merck Sharp & Dohme, or MSD, in all nations other than the United States and Canada while its German ancestor is dubbed EMD Group is America. And that’s led to some understandable tensions, especially when it comes to digital marketing and website domain procurement, as FiercePharma reports.

Merck & Co. Responded to these scuffles with a trademark infringement suit against Merck KGaA at the beginning of the year, claiming that the latter firm isn’t playing in good faith when it comes to its existing territorial naming agreements.

But Merck KGaA isn’t going down without a fight. In fact, the drugmaker has lobbed allegations of trademark impropriety right back at its generational descendent, arguing that Merck has ducked its responsibility to identify as MSD in much of the world.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.